Page last updated: 2024-12-08

Nomega-hydroxy-nor-l-arginine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID446124
CHEMBL ID1234777
CHEBI ID191070
SCHEMBL ID4097591
SCHEMBL ID17905716

Synonyms (43)

Synonym
nnh ,
nor-n-omega-hydroxy-l-arginine
n-hydroxy-nor-arginine
DB02381
(2s)-2-amino-4-(((hydroxyamino)iminomethyl)amino)butanoic acid
n-hydroxy-nor-l-arginine
nomega-hydroxy-nor-l-arginine
nor-noha
HSCI1_000281
chembl1234777 ,
bdbm50008099
CHEBI:191070
(2s)-2-amino-4-[[amino-(hydroxyamino)methylidene]amino]butanoic acid
189302-40-7
AKOS006279536
nomega-hydroxy-nor-l-arginine dihydrochloride
291758-32-2
n|o-hydroxy-nor-l-arginine dihydrochloride
(2s)-2-amino-4-[(e)-2-hydroxycarbamimidamido]butanoic acid
gtpl5091
SCHEMBL4097591
n?-hydroxy-nor-l-arginine dihydrochloride
J842.499C ,
U0F1149OFR ,
n.omega.-hydroxy-nor-l-arginine
butanoic acid, 2-amino-4-(((hydroxyamino)iminomethyl)amino)-, (s)-
HMS3650A03
butanoic acid,2-amino-4-[[(hydroxyamino)iminomethyl]amino]-,(2s)-
DTXSID40332211
unii-u0f1149ofr
SCHEMBL17905716
J-012212
n-omega'-hydroxy-l-norarginine
n--hydroxy-l-norarginine acetate salt
(2s)-2-amino-4-(n'-hydroxycarbamimidamido)butanoic acid
n-omega-hydroxy-nor-l-arginine dihydrochloride
n-omega-hydroxy-l-norarginine
Q27088086
SR-01000946755-1
sr-01000946755
(2s)-4-[[amino-(hydroxyamino)methylidene]amino]-2-azaniumylbutanoate
(s)-2-amino-4-(3-hydroxyguanidino)butanoic acid
(2s)-2-amino-4-{[amino(hydroxyamino)methylidene]amino}butanoic acid
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
L-alpha-amino acidAny alpha-amino acid having L-configuration at the alpha-carbon.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (4)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Arginase-1Homo sapiens (human)IC50 (µMol)3.68000.31101.60546.0000AID1540248; AID1695181
Arginase-1 Rattus norvegicus (Norway rat)IC50 (µMol)1.40000.80001.20002.0000AID1128922; AID1724055
Arginase-2, mitochondrialHomo sapiens (human)Ki0.05100.00850.34381.6000AID1370773; AID1724057
Arginase-1Bos taurus (cattle)IC50 (µMol)2.70002.70002.70002.7000AID1695179
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Arginase-1Homo sapiens (human)Kd0.28200.00500.69873.6000AID1370772; AID1724056
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (27)

Processvia Protein(s)Taxonomy
urea cycleArginase-1Homo sapiens (human)
adaptive immune responseArginase-1Homo sapiens (human)
arginine catabolic processArginase-1Homo sapiens (human)
negative regulation of T cell proliferationArginase-1Homo sapiens (human)
defense response to protozoanArginase-1Homo sapiens (human)
innate immune responseArginase-1Homo sapiens (human)
negative regulation of activated T cell proliferationArginase-1Homo sapiens (human)
negative regulation of type II interferon-mediated signaling pathwayArginase-1Homo sapiens (human)
positive regulation of neutrophil mediated killing of fungusArginase-1Homo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionArginase-1Homo sapiens (human)
arginine catabolic process to ornithineArginase-1Homo sapiens (human)
urea cycleArginase-2, mitochondrialHomo sapiens (human)
ureteric bud developmentArginase-2, mitochondrialHomo sapiens (human)
adaptive immune responseArginase-2, mitochondrialHomo sapiens (human)
negative regulation of type 2 immune responseArginase-2, mitochondrialHomo sapiens (human)
nitric oxide biosynthetic processArginase-2, mitochondrialHomo sapiens (human)
striated muscle contractionArginase-2, mitochondrialHomo sapiens (human)
regulation of interleukin-1 beta productionArginase-2, mitochondrialHomo sapiens (human)
negative regulation of interleukin-13 productionArginase-2, mitochondrialHomo sapiens (human)
negative regulation of interleukin-17 productionArginase-2, mitochondrialHomo sapiens (human)
negative regulation of tumor necrosis factor productionArginase-2, mitochondrialHomo sapiens (human)
innate immune responseArginase-2, mitochondrialHomo sapiens (human)
negative regulation of macrophage inflammatory protein 1 alpha productionArginase-2, mitochondrialHomo sapiens (human)
negative regulation of chemokine (C-C motif) ligand 4 productionArginase-2, mitochondrialHomo sapiens (human)
negative regulation of chemokine (C-C motif) ligand 5 productionArginase-2, mitochondrialHomo sapiens (human)
negative regulation of defense response to bacteriumArginase-2, mitochondrialHomo sapiens (human)
regulation of reactive oxygen species biosynthetic processArginase-2, mitochondrialHomo sapiens (human)
negative regulation of activated CD8-positive, alpha-beta T cell apoptotic processArginase-2, mitochondrialHomo sapiens (human)
negative regulation of CD4-positive, alpha-beta T cell proliferationArginase-2, mitochondrialHomo sapiens (human)
positive regulation of cellular senescenceArginase-2, mitochondrialHomo sapiens (human)
arginine catabolic process to ornithineArginase-2, mitochondrialHomo sapiens (human)
urea cycleArginase-1Bos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (3)

Processvia Protein(s)Taxonomy
protein bindingArginase-1Homo sapiens (human)
arginase activityArginase-1Homo sapiens (human)
manganese ion bindingArginase-1Homo sapiens (human)
arginase activityArginase-2, mitochondrialHomo sapiens (human)
protein bindingArginase-2, mitochondrialHomo sapiens (human)
manganese ion bindingArginase-2, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (9)

Processvia Protein(s)Taxonomy
extracellular regionArginase-1Homo sapiens (human)
extracellular spaceArginase-1Homo sapiens (human)
nucleusArginase-1Homo sapiens (human)
cytosolArginase-1Homo sapiens (human)
azurophil granule lumenArginase-1Homo sapiens (human)
specific granule lumenArginase-1Homo sapiens (human)
cytosolArginase-1Homo sapiens (human)
cytoplasmArginase-1Homo sapiens (human)
mitochondrial matrixArginase-2, mitochondrialHomo sapiens (human)
cytoplasmArginase-2, mitochondrialHomo sapiens (human)
mitochondrionArginase-2, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (14)

Assay IDTitleYearJournalArticle
AID1370772Binding affinity to arginase 1 (unknown origin)2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Small molecule immuno-oncology therapeutic agents.
AID1724057Inhibition of human Arg2 at pH 7.52020Bioorganic & medicinal chemistry, 09-15, Volume: 28, Issue:18
Boronic acid-based arginase inhibitors in cancer immunotherapy.
AID1695179Inhibition of recombinant bovine liver ARGI using L-arginine as substrate incubated for 60 mins by spectroscopic analysis2020RSC medicinal chemistry, May-01, Volume: 11, Issue:5
Synthesis, evaluation and molecular modelling of piceatannol analogues as arginase inhibitors.
AID1128922Inhibition of rat liver arginase2014European journal of medicinal chemistry, Apr-09, Volume: 76The applications of binuclear metallohydrolases in medicine: recent advances in the design and development of novel drug leads for purple acid phosphatases, metallo-β-lactamases and arginases.
AID1501188Inhibition of bovine liver arginase assessed as reduction in urea production using L-arginine as substrate after 60 mins in presence of MnCl2 by alpha-isonitrosopropiophenone reagent based spectrophotometric analysis2017Journal of natural products, 09-22, Volume: 80, Issue:9
Cyperaceae Species Are Potential Sources of Natural Mammalian Arginase Inhibitors with Positive Effects on Vascular Function.
AID1724056Binding affinity to human Arg1 at pH 8.52020Bioorganic & medicinal chemistry, 09-15, Volume: 28, Issue:18
Boronic acid-based arginase inhibitors in cancer immunotherapy.
AID1695181Inhibition of recombinant human liver ARGI using L-arginine as substrate incubated for 60 mins by spectroscopic analysis2020RSC medicinal chemistry, May-01, Volume: 11, Issue:5
Synthesis, evaluation and molecular modelling of piceatannol analogues as arginase inhibitors.
AID1370774Oral bioavailability in rat2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Small molecule immuno-oncology therapeutic agents.
AID1370775Half life in rat2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Small molecule immuno-oncology therapeutic agents.
AID1540248Inhibition of human recombinant arginase 1 expressed in Escherichia coli BL21 (DE3) assessed as reduction in urea production using L-arginine as substrate in presence of MnSO4 incubated for 60 mins by o-phthaldialdehyde/N-(1-naphthyl)ethylene-diamine dihy2019Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17
Discovery of
AID1724055Inhibition of rat Arg1 at pH 7.42020Bioorganic & medicinal chemistry, 09-15, Volume: 28, Issue:18
Boronic acid-based arginase inhibitors in cancer immunotherapy.
AID1540249Inhibition of human recombinant arginase 2 H331 to I354 deletion mutant expressed in Escherichia coli BL21 (DE3) assessed as reduction in urea production using L-arginine as substrate in presence of MnSO4 incubated for 60 mins by colorimetric assay2019Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17
Discovery of
AID1370773Inhibition of arginase 2 (unknown origin)2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Small molecule immuno-oncology therapeutic agents.
AID1128921Inhibition of mouse macrophage arginase2014European journal of medicinal chemistry, Apr-09, Volume: 76The applications of binuclear metallohydrolases in medicine: recent advances in the design and development of novel drug leads for purple acid phosphatases, metallo-β-lactamases and arginases.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's4 (66.67)24.3611
2020's2 (33.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.56 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.51 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (50.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other3 (50.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]